Document is current

Article History

Received: 12 August 2020

Accepted: 9 October 2020

First Online: 23 October 2020

Compliance with ethical standards

:

: KTD has served as a consultant/advisory board member Seattle Genetics and QED Therapeutics; consulting fees from Jackson Laboratories; and has received commercial research grants (to institution) from Eli Lilly. JLH reports serving as a consultant/advisory board member for Clovis, AstraZeneca, Merck, Tesaro, Ipsen, Deciphera and receiving commercial research grants (to Institution) Mersana, Deciphera, Sanofi, Amgen, Boston Biomedical, Karyopharm, Exelexis, Beigene, EMD-Serono. SVL reports serving as a paid consultant/advisory board member for AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Catalyst, Celgene, G1 Therapeutics, Genentech/Roche, Guardant Health, Janssen, Lilly, LOXO, MSD, Pfizer, PharmaMar, Regeneron, and Takeda and receiving commercial research grants (to Institution) from Alkermes, AstraZeneca, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Genentech/Roche, Eli Lilly, Lycera, Merck, Merus, Molecular Partners, Pfizer, Rain Therapeutics, RAPT, Spectrum and Turning Point Therapeutics. SC reports serving as a paid consultant/advisory board for GSK and Esai. GIS has received research funding from Eli Lilly, Merck KGaA/EMD-Serono, Merck, and Sierra Oncology. He has served on advisory boards for Pfizer, Eli Lilly, G1 Therapeutics, Roche, Merck KGaA/EMD-Serono, Sierra Oncology, Bicycle Therapeutics, Fusion Pharmaceuticals, Cybrexa Therapeutics, Astex, Almac, Ipsen, Bayer, Angiex, Daiichi Sankyo, Seattle Genetics, Boehringer Ingelheim, ImmunoMet, Asana, Artios, Atrin and Concarlo Holdings. In addition, he holds a patent entitled, “Dosage regimen for sapacitabine and seliciclib,” also issued to Cyclacel Pharmaceuticals, and a pending patent, entitled, “Compositions and Methods for Predicting Response and Resistance to CDK4/6 Inhibition,” together with Liam Cornell. TS and JL are employees of Astex. GOC, JGS, KB, LN, JBT, M-JL, CG, JH, AM, PI, JHD, and APC declare no conflicts of interest.

: This study was conducted in accordance with the International Conference on Harmonization, Good Clinical Practice guidelines, and the ethical principles outlined in the Declaration of Helsinki 2008. The study protocol, amendments, informed consent, and other information that required approval were reviewed and approved by the Central Institutional Review Board, National Cancer Institute, in accordance with the International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use Good Clinical Practice and applicable country-specific requirements, including US 21 Code of Federal Regulations 312.3(b) for the constitution of independent ethics committees. All participants provided written informed consent prior to study entry.

: Participant consent for publication was obtained and on file at the respective participating site.